当前位置:首页 - 行情中心 - 泰林生物(300813) - 财务分析 - 现金流量表

泰林生物

(300813)

  

流通市值:15.56亿  总市值:22.16亿
流通股本:8512.61万   总股本:1.21亿

现金流量表

报告期2026-09-302026-06-302026-03-312025-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金290,556,366.15191,499,433.1478,884,224.82337,098,567.74
  收到的税费返还6,956,632.314,539,251.742,421,682.59,547,174.16
  收到其他与经营活动有关的现金33,752,716.395,639,562.497,469,390.529,117,118.59
  经营活动现金流入小计331,265,714.85201,678,247.3788,775,297.84355,762,860.49
  购买商品、接受劳务支付的现金93,751,504.5276,247,301.0127,065,991.64111,933,636.07
  支付给职工以及为职工支付的现金117,625,644.7180,701,070.4747,095,100.53138,395,438.37
  支付的各项税费23,317,080.2712,915,916.828,620,321.8623,584,464.08
  支付其他与经营活动有关的现金50,559,553.3210,713,389.599,550,894.734,127,312.53
  经营活动现金流出小计285,253,782.82180,577,677.8992,332,308.73308,040,851.05
  经营活动产生的现金流量净额46,011,932.0321,100,569.48-3,557,010.8947,722,009.44
二、投资活动产生的现金流量:
  取得投资收益收到的现金---9,384,212.49
  收到的其他与投资活动有关的现金1,252,807,517.9817,940,739.86361,909,860.581,241,004,000
  投资活动现金流入小计1,252,807,517.9817,940,739.86361,909,860.581,250,388,212.49
  购建固定资产、无形资产和其他长期资产支付的现金41,091,001.7624,582,304.268,774,544.546,885,597.33
  投资支付的现金---2,000,000
  支付其他与投资活动有关的现金1,141,043,001.77701,800,000283,000,0001,199,100,000
  投资活动现金流出小计1,182,134,003.53726,382,304.26291,774,544.51,247,985,597.33
  投资活动产生的现金流量净额70,673,514.3791,558,435.670,135,316.082,402,615.16
三、筹资活动产生的现金流量:
  吸收投资收到的现金17,051,580---
  收到其他与筹资活动有关的现金---11,174,000
  筹资活动现金流入平衡项目0--0
  筹资活动现金流入小计17,051,580--11,174,000
  偿还债务支付的现金---3,669,656.41
  分配股利、利润或偿付利息支付的现金15,565,021.743,599,437.47-24,719,669.22
  其中:子公司支付给少数股东的股利、利润---479,825.42
  支付其他与筹资活动有关的现金32,372,647.3232,285,577.5147,169.8123,509,544.31
  筹资活动现金流出小计47,937,669.0635,885,014.9847,169.8151,898,869.94
  筹资活动产生的现金流量净额-30,886,089.06-35,885,014.98-47,169.81-40,724,869.94
四、汇率变动对现金及现金等价物的影响-1,149,766.14-455,933.89-422,963.92-732,533.59
五、现金及现金等价物净增加额84,649,591.276,318,056.2166,108,171.468,667,221.07
  加:期初现金及现金等价物余额78,545,303.5378,545,303.5378,545,303.5369,878,082.46
  期末现金及现金等价物余额163,194,894.73154,863,359.74144,653,474.9978,545,303.53
补充资料:
  净利润-20,372,823.69-16,286,074.7
  资产减值准备-886,249.41-3,963,381.82
  固定资产和投资性房地产折旧-7,893,215.04-15,919,807.65
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-7,893,215.04-15,919,807.65
  无形资产摊销-397,880.46-749,661.96
  长期待摊费用摊销-2,147,909.06-4,160,512.79
  固定资产报废损失-176,221.93-371,037.57
  公允价值变动损失----20,441.21
  财务费用--800,082.83--2,274,959.57
  投资损失--1,641,315.01--4,358,519.68
  递延所得税--350,073.92--929,625.94
  其中:递延所得税资产减少-10,895.81--81,679
    递延所得税负债增加--360,969.73--847,946.94
  存货的减少--11,117,465.23-13,861,292.84
  经营性应收项目的减少--1,348,502.01--1,227,940.18
  经营性应付项目的增加-2,850,370.73--4,400,013.8
  其他-1,633,338.16-5,621,740.49
  现金的期末余额-154,863,359.74-78,545,303.53
  减:现金的期初余额-78,545,303.53-69,878,082.46
  现金及现金等价物的净增加额-76,318,056.21-8,667,221.07
公告日期2026-10-302026-08-272026-04-302026-03-27
审计意见(境内)标准无保留意见
TOP↑